Skip to content
Open access

Transplantation Strategies in Treatment of Primary Plasma Cell Leukemia in Germany-A Multi-Center Analysis.

Sep 2026 · European Journal of Haematology · 0 citations · 33 references
Medicine

TL;DR

The data support recent recommendations advising treating patients with tandem transplantation regimes and support the idea that the optimal consolidation strategy remains to be defined.

Abstract

Objectives

Primary plasma cell leukemia (pPCL) is a rare disease with poor outcomes. As data on randomized phase-III trials are lacking, treatment recommendations are predominately based on retrospective analyses incorporating time periods with outdated therapies. Thus, the optimal consolidation strategy remains to be defined.

Methods

We conducted a retrospective, multi-center analysis with 49 transplant-eligible patients diagnosed with pPCL between 2011 and 2025 focusing on different stem cell transplantation (SCT) strategies as consolidation treatment in first remission: single autologous (auto) or single allogeneic (allo) SCT versus patients with tandem cell therapy strategies (auto-auto, allo-auto, auto-chimeric antigen receptor therapy).

Results

The median follow-up after first SCT was 31 months. The cumulative incidence of initiating next treatment was lower after tandem cell therapy compared to single SCT (at 12 months: 42% vs. 57%, p = 0.006). Moreover, in a multivariable analysis incorporating cytogenetic risk and response to induction therapy, tandem transplantation strategies tended to be the only independent predictor for prolonged time to next treatment (TTNT, p = 0.077). Noteworthy, differences in TTNT between patients with a single SCT and patients with tandem cell therapy did not translate into an improved overall survival, possibly due to potent salvage therapies.

Conclusions

Our data support recent recommendations advising treating patients with tandem transplantation regimes.

Read PDF

Similar papers

Open access Sep 2026

Treatment Patterns, Outcomes and Survival Trends in T-Cell Prolymphocytic Leukemia: A Nationwide Population-Based Study in the Netherlands.

BACKGROUND T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive mature T-cell malignancy with limited therapeutic options. Alemtuzumab remains the backbone of therapy, and fit responders are consolidated with allogeneic stem cell transplantation (alloSCT). However, contemporary population-level outcomes remain...

M. Brink, Arie C. van der Spek, J. Doorduijn et al. · 0 citations
Open access Oct 2026

Conditioning Regimens Prior to Autologous Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Analysis of the short- and long-term outcomes in relation to HDCT regimens revealed the best rates achieved by the LEAM program, however, the multivariate regression analysis excluded the value of HDCT regimens for OS in r/r cHL.

G. Petrova, И. С. Монин, N. Zolotaikina et al. · 0 citations
Open access Sep 2026

Predictors of autologous hematopoietic stem cell transplantation efficacy in patients with multiple myeloma

Background. Multiple myeloma (MM) remains a chronic hematologic malignancy. However, treatment outcomes have improved significantly due to the introduction of new targeted agents and high-dose therapy with autologous hematopoietic stem cell transplantation (auto-HSCT) into clinical practice. Several researchers have de...

M. Solovev, L. Mendeleeva, M. V. Solov'eva · 0 citations
Open access Sep 2026

Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis.

The effect of different maintenance therapies on outcome after autologous hematopoietic cell transplantation (AHCT) was analyzed in newly diagnosed multiple myeloma (NDMM) patients using global real-world data. NDMM patients transplanted between 2013 and 2017 were selected from the Worldwide Network for Blood and Marro...

Andrew J. Cowan, L. Gras, R. Cassano et al. · 0 citations
Open access Sep 2026

Second autologous hematopoietic stem cell transplantation in multiple myeloma.

ASCT2 is a feasible salvage strategy in selected Indian patients with multiple myeloma, yielding favorable outcomes with acceptable toxicity, and three patients remain alive and in sustained remission.

Disha Kakkar, Vivek Mohan, Hamza Dalal et al. · 0 citations
Open access Aug 2026

Timing of autologous stem cell transplantation and induction response in central nervous system lymphoma

Primary and secondary central nervous system lymphomas (PCNSL and SCNSL, respectively) are aggressive non-Hodgkin lymphomas with high relapse risk. Methotrexate rarely achieves durable remission, necessitating combination therapy or consolidation. Although high-dose busulfan and thiotepa (BuTT) conditioning followed by...

Yusuke Higuchi, H. Tatetsu, Taichi Hirano et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.